Hepatitis C: UPDATE Post AASLD ’12 - Progress in IFN-Free Drugs & Vaccines - Gilead and Abbott vying for the Top Two Slots - Third Place Goes to ....?
Impressive Sustained Virologic Response (SVR) rates by drugs in the pipeline for HCV pts – GT1, Null, and Naïve seems to have become the norm. At AASLD 2012: (i) GILD presented interim data from the ongoing PhII ELECTRON study – the fixed-dose combination of Sofosbuvir (SOF, formerly GS-7977, PMI) + GS-5885 (NS5A Inhibitor – NS5AI); (ii) Abbott presented PhIIb data of AVIATOR trial with its tirade of DAAs (ABT-450, PI/r + ABT-333, PMI + ABT-267, NS5AI); (iii) Vertex reported safety and efficacy data of its oral, novel nucleotide analog – VX-135 (ALS-2200, PMI); (iv) Merck presented data of its second-generation PI, MK-5172 in combination with NS5A inhibitor, MK-8742; and (iv) Bristol-Myers Squibb (BMS) and Boehringer Ingelheim both presented new data of their HCV. Based on the proposed future development plans announced, we expect… for more detail, please read our report released on 20th Nov. 2012, titled, 'Hepatitis C: UPDATE Post AASLD ’12 - Progress in IFN-Free Drugs & Vaccines - Gilead and Abbott vying for the Top Two Slots - Third Place Goes to ....?'
More Publications
Hepatitis C: Battlefield at AASLD ‘11 - Next Wave: IFN-Free Drugs with Safety and Dosing Advantage
US$ 2,000.00
October 2011
13 pages
Anthrax - Pipeline Review, H2 2020
US$ 2,000.00
July 2020
126 pages
PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
US$ 90.00
October 2011
4 pages
